Evidence map›Paper›PMID 34450083›Full record

ArticleLancet (London, England)2021

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

NCD Risk Factor Collaboration (NCD-RisC)

Erratum issued 4 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 4 registered trials, which are not on this map. Cited by 1,996 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,996citing papers in PubMed, 6 pooled it
381.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05814068 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Active Screening of Arterial Hypertension by Community Outreach Workers in the Cayenne Metropolitan Area to Reduce the Incidence of Cardiovascular Disease

TypeinterventionalSponsorCentre Hospitalier de CayenneRan2023 to 2025Enrolled50,000ConditionsHigh Blood PressureArmsantihypertensive drug treatment
NCT05880056 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

A Prospective, Multicenter, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension

TypeinterventionalSponsorGenuine Research Center, EgyptRan2024 to 2025Enrolled406ConditionsEssential HypertensionArmsNerkardou (5 mg) & (10 mg)
NCT06141200 phase3unknown statusnot on this mapstarted 2024, after this paper: background citation

Efficacy and Safety of Roselle in Patients With Grade 1 Essential Hypertension: A Phase III, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial

TypeinterventionalSponsorNatural Wellness EgyptRan2024 to 2025Enrolled286ConditionsEssential HypertensionArmsNW Roselle, Captopril 25Mg Tab
NCT07695376 recruitingnot on this mapstarted 2026, after this paper: background citation

CArdiovascular Risk Assessment Via Multimodal Data Analysis Enabling Personalised Prevention Strategies Targeting MEnopausaL Women - Observational Study

Typeobservational_patient_registrySponsorBiogipuzkoa Health Research InstituteRan2026 to 2028Enrolled3,000ConditionsPerimenopause, Menopause, Cardiovascular (CV) Risk, Women (Between 30 to 60 Years Old)
3 · Its place in the literature

Who cites it

1,996 citing papers in PubMed, 6 syntheses or guidelines pooled it, 3,502 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Accelerated epigenetic age in hypertension: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial.Journal of clinical hypertension (Greenwich, Conn.) · 2026
    Trial
  17. Trial
  18. Trial
  19. Review
  20. Review

1,936 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 14 institutions in 9 countries.

NCD Risk Factor Collaboration (NCD-RisC)
Imperial College London · GBInstitut Pasteur de Lille · FRNational University of Samoa · WSÉco-Anthropologie · FRCentre Hospitalier Universitaire de Toulouse · FRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FRUniversité Paris Cité · FRCharles University · CZFederal Almazov North-West Medical Research Centre · RUHarvard University · USInteractions Gène-Environnement en Physiopathologie Cardio-Vasculaire · FRUniversity of California, Berkeley · USUniversity of Indonesia · IDUNSW Sydney · AU

Funding

CVD Epidemiology Training Program in Behavior, the Environment and Global HealthT32HL098048 · NHLBI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Goodarz Danaei, ERIC B RIMM · 2009 to 2026
$6.9M
Endocrine and metabolic diseases in rural South Africa-establishing burden and improving detectionK43TW010698 · FIC · WITS HEALTH CONSORTIUM (PTY), LTD · PI WADE, ALISHA NICOLE · 2017 to 2021
$581k
British Heart FoundationFIC NIH HHS K43 TW010698Medical Research Council G0400519Medical Research Council MC_PC_21000Medical Research Council MC_PC_21001Medical Research Council MC_UP_A620_1014Medical Research Council MC_UP_A620_1016Medical Research Council MC_UU_00006/1Medical Research Council MC_UU_00017/1Medical Research Council MC_UU_12011/3NHLBI NIH HHS T32 HL098048
6 · The paper itself

Abstract

backgroundHypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories.

methodsWe used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age.

findingsThe number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran.

interpretationImprovements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings.

fundingWHO.

Indexed as

AdultAgedAntihypertensive AgentsFemaleGlobal HealthHumansHypertensionMaleMiddle AgedPrevalenceAntihypertensive Agents

Identifiers

PMID34450083
PMCPMC8446938
OpenAlexW3193823764

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.